Assenagon Asset Management S.A. Purchases Shares of 12,058 Glaukos Corporation $GKOS

Key Points

• Assenagon Asset Management S.A. acquired 12,058 shares of Glaukos Corporation, valued at approximately $1,245,000, in the second quarter.
• Glaukos reported a revenue increase of 29.7% year-over-year, with quarterly revenue totaling $124.12 million, exceeding analyst expectations.
• Analysts have largely rated Glaukos stock positively, with one "strong-buy," ten "buy," and a consensus price target of $123.58.

Assenagon Asset Management S.A. acquired a new position in Glaukos Corporation (NYSE:GKOS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,058 shares of the medical instruments supplier's stock, valued at approximately $1,245,000.

Other hedge funds have also recently modified their holdings of the company. Bessemer Group Inc. lifted its position in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 158 shares during the last quarter. Whipplewood Advisors LLC increased its holdings in shares of Glaukos by 3,957.1% in the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 277 shares during the period. First Horizon Advisors Inc. lifted its holdings in Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 159 shares during the period. Versant Capital Management Inc grew its position in shares of Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 327 shares during the period. Finally, Bayforest Capital Ltd purchased a new position in shares of Glaukos in the first quarter valued at approximately $141,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

Shares of GKOS opened at $79.95 on Friday. The stock has a market capitalization of $4.59 billion, a PE ratio of -48.45 and a beta of 0.77. The business's fifty day moving average price is $89.69 and its 200 day moving average price is $93.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. Glaukos Corporation has a 12-month low of $77.10 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million for the quarter, compared to analysts' expectations of $115.49 million. During the same period in the prior year, the company earned ($0.52) earnings per share. The firm's revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities research analysts forecast that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on GKOS shares. William Blair raised Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. UBS Group raised their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Truist Financial decreased their target price on shares of Glaukos from $126.00 to $120.00 and set a "buy" rating on the stock in a research report on Monday, September 22nd. Wells Fargo & Company lifted their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Finally, Mizuho set a $130.00 price objective on Glaukos in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $123.58.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.